Results 11 to 20 of about 94,347 (282)

Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer

European Journal of Medical Research
Breast cancer (BC) has a high mortality rate and is one of the most common malignancies in the world. Initially, BC was considered non-immunogenic, but a paradigm shift occurred with the discovery of tumor-infiltrating lymphocytes (TILs) and regulatory T
Maryam Jama, Yasser Tabana, Khaled H. Barakat   +2 more
doaj   +3 more sources

Cytotoxic T-lymphocyte Associated Antigen-4 (CTLA-4) Polymorphism, Cancer, and Autoimmune Diseases

AIMS Medical Science, 2017
Immune system dysfunction is one of the key features in onset and development of cancer and autoimmunity. Cytotoxic T-lymphocyte-antigen-4 (CTLA-4), as a leader immune checkpoint plays a crucial effects in the regulation of immune suppression and ...
Maryam Tanhapour, Asad Vaisi-Raygani, Mozafar Khazaei, Zohreh Rahimi, Tayebeh Pourmotabbed   +4 more
doaj   +2 more sources

Progress in Research on Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) and Bladder Cancer [PDF]

Annals of Urologic Oncology, 2019
Cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) was first discovered in 1987 and confirmed to be a protein that is mainly expressed on the surface of activated lymphocytes.
Wei-Ming Fang, Chun Chen
doaj   +2 more sources

Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches [PDF]

Biology of Blood and Marrow Transplantation, 2017
Minor histocompatibility antigen (miHA) mismatches have been related to graft-versus-host disease (GVHD) after allogeneic stem cell transplantation, but this association remains controversial due to the lack of consistency in the results obtained by different groups. The CTLA-4 genotype of the donor has been reported to be relevant in the appearance of
David Gallardo, Anna Bosch-Vizcaya, Rocío Rodríguez-Romanos, Nazly Santos, Ismael Buño, Rafael de la Cámara, Salut Brunet, Antonio Jiménez-Velasco, Marcos González, Jose B. Nieto, Carolina Martínez-Laperche, Carlos Vallejo, Christelle Ferrá, Antònia Sampol, Javier López-Jiménez, Jose A. Pérez-Simón, Carmen Martínez, Jose L. Díez   +17 more
openaire   +8 more sources

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade [PDF]

Cell, 2018
CTLA-4 immune checkpoint blockade is clinically effective in a subset of patients with metastatic melanoma. We identify a subcluster of MAGE-A cancer-germline antigens, located within a narrow 75 kb region of chromosome Xq28, that predicts resistance uniquely to blockade of CTLA-4, but not PD-1.
Shukla, Sachet A., Bachireddy, Pavan, Schilling, Bastian, Galonska, Christina, Zhan, Qian, Bango, Clyde, Langer, Rupert, Lee, Patrick C., Gusenleitner, Daniel, Keskin, Derin B., Babadi, Mehrtash, Mohammad, Arman, Gnirke, Andreas, Clement, Kendell, Cartun, Zachary J., Van Allen, Eliezer M., Miao, Diana, Huang, Ying, Snyder, Alexandra, Merghoub, Taha, Wolchok, Jedd D., Garraway, Levi A., Meissner, Alexander, Weber, Jeffrey S., Hacohen, Nir, Neuberg, Donna, Potts, Patrick R., Murphy, George F., Lian, Christine G., Schadendorf, Dirk, Hodi, F. Stephen, Wu, Catherine J.   +31 more
openaire   +3 more sources

Antigen Exposure during Enhanced CTLA-4 Expression Promotes Allograft Tolerance In Vivo [PDF]

The Journal of Immunology, 2006
AbstractThe role of CTLA-4 in tolerance is primarily inferred from knockout and blocking studies. Anti-CD45RB mediates allograft tolerance in mice by inducing CTLA-4 expression on CD4 cells, providing a novel opportunity to determine how therapeutic enhancement of CTLA-4 promotes tolerance.
Paolo R O, Salvalaggio, Geoffrey, Camirand, Charlotte E, Ariyan, Songyan, Deng, Linda, Rogozinski, Giacomo P, Basadonna, David M, Rothstein   +6 more
openaire   +2 more sources

CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen [PDF]

The Journal of Immunology, 2001
Abstract p53 is an attractive target for cancer immunotherapy because it is overexpressed in a high proportion of many different types of tumors. However, it is also expressed in normal tissues and acts as a toleragen in vivo. Previously, detailed examination of the repertoire specific for the murine p53261–269 epitope in conventional ...
J, Hernández, A, Ko, L A, Sherman
openaire   +2 more sources

Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) [PDF]

Cancer, 2007
AbstractCancer immunotherapy centers on modulating the host's tumor‐directed immune response. One promising approach involves augmentation of cell‐mediated immunity by interrupting T‐cell pathways responsible for immune down‐regulation or tolerance. The discovery of cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) and its role as a key negative regulator for ...
Steven J, O'Day, Omid, Hamid, Walter J, Urba   +2 more
openaire   +2 more sources

CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4 (CTLA-4) GENE POLYMORPHISMS IN BRONCHIAL ASTHMA. [PDF]

International Journal of Advanced Research, 2016
El asma es un trastorno poligénico y multifactorial, estos factores son tanto genéticos como ambientales. El gen CTLA-4 se encuentra en el cromosoma 2q33, un inhibidor clave de la activación de las células T, se expresa solo en las células T auxiliares activadas y desempeña un papel regulador negativo en la respuesta de las células T. Los polimorfismos
SouadMohamed Aboazma, AymanZ. Elsamanoudy, Naglaa Mokhtar, Ahmed Mohsen, AsemA. Hewidy   +4 more
openaire   +1 more source

No association of CTLA-4 polymorphisms with susceptibility to Behcet disease [PDF]

, 2009
Background: Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is a key negative regulator of T lymphocytes and has been shown to be associated with a number of autoimmune diseases. The present study was performed to assess the association between CTLA-
Du, L., Hou, S., Kijlstra, A., Yang, P., Zhou, H.   +4 more
core   +2 more sources